These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 26137119)
1. Clinical significance of Yu L; Ma L; Tu Q; Zhang YI; Chen Y; Yu D; Yang S Oncol Lett; 2015 Jun; 9(6):2633-2638. PubMed ID: 26137119 [TBL] [Abstract][Full Text] [Related]
2. The BRAF V600E Mutation and Clinicopathological Changes Among Patients With Hashimoto Thyroiditis, Papillary Thyroid Carcinoma With Hashimoto Thyroiditis, and Nodular Goiter. Deng J; Yu L; Luo S; Yang Z; Liu J; Liao L Appl Immunohistochem Mol Morphol; 2024 Aug; 32(7):345-349. PubMed ID: 38775148 [TBL] [Abstract][Full Text] [Related]
3. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825 [TBL] [Abstract][Full Text] [Related]
4. Association Between BRAF Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398 [TBL] [Abstract][Full Text] [Related]
5. Predictive Value of BRAF Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513 [TBL] [Abstract][Full Text] [Related]
6. Clinical Analysis of BRAF Dong SY; Chen J; Xia EJ; Lin RX; Du HY; Wang OC; Zhang XH; Hao RT Am Surg; 2020 May; 86(5):450-457. PubMed ID: 32684022 [TBL] [Abstract][Full Text] [Related]
7. Younger Than 55 Years Old and Lai Y; Gu Y; Yu M; Deng J Int J Gen Med; 2023; 16():1403-1414. PubMed ID: 37155469 [TBL] [Abstract][Full Text] [Related]
8. BRAF Dong SY; Zeng RC; Jin LP; Yang F; Zhang XJ; Yao ZH; Zhang XH; Wang OC Oncol Lett; 2017 Oct; 14(4):4122-4134. PubMed ID: 28943919 [TBL] [Abstract][Full Text] [Related]
9. Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with Li GY; Tan HL; Chen P; Hu HY; Liu M; Ou-Yang DJ; Khushbu RA; Pun D; Li JD; Zhang ZP; Yang Q; Huang P; Chang S Cancer Manag Res; 2020; 12():3371-3378. PubMed ID: 32494201 [TBL] [Abstract][Full Text] [Related]
10. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer. Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461 [TBL] [Abstract][Full Text] [Related]
11. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147 [TBL] [Abstract][Full Text] [Related]
12. Co-existence of Ren H; Shen Y; Hu D; He W; Zhou J; Cao Y; Mao Y; Dou Y; Xiong W; Xiao Q; Zhang Y; Su X Cancer Manag Res; 2018; 10():1005-1013. PubMed ID: 29760568 [TBL] [Abstract][Full Text] [Related]
13. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study. Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698 [TBL] [Abstract][Full Text] [Related]
14. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive evaluation of risk factors for lymph node metastasis in patients with papillary thyroid carcinoma. Dong Y; Wang D; Luo Y; Chen L; Bai H; Shen Y; Zhang Y; Chen X; Su X; Zhao J; Liu H; Lu J; Yao Z; Zhao Y; He C; Li X Oncol Lett; 2021 Mar; 21(3):188. PubMed ID: 33574927 [TBL] [Abstract][Full Text] [Related]
16. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656 [TBL] [Abstract][Full Text] [Related]
17. Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients. Shin MK; Kim JW; Min SK; Lee DJ; Kim JH; Lee SC; Chung BW; Ju YS Oncol Lett; 2015 Sep; 10(3):1882-1888. PubMed ID: 26622769 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma. Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426 [TBL] [Abstract][Full Text] [Related]
19. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706 [TBL] [Abstract][Full Text] [Related]
20. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. Lee ST; Kim SW; Ki CS; Jang JH; Shin JH; Oh YL; Kim JW; Chung JH J Clin Endocrinol Metab; 2012 Jul; 97(7):2299-306. PubMed ID: 22500044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]